AU2002322481A1 - Use of r-nsaid compounds for anti-hiv treatment - Google Patents

Use of r-nsaid compounds for anti-hiv treatment

Info

Publication number
AU2002322481A1
AU2002322481A1 AU2002322481A AU2002322481A AU2002322481A1 AU 2002322481 A1 AU2002322481 A1 AU 2002322481A1 AU 2002322481 A AU2002322481 A AU 2002322481A AU 2002322481 A AU2002322481 A AU 2002322481A AU 2002322481 A1 AU2002322481 A1 AU 2002322481A1
Authority
AU
Australia
Prior art keywords
hiv treatment
nsaid compounds
nsaid
compounds
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002322481A
Other languages
English (en)
Inventor
Kenton Zavitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myriad Genetics Inc
Original Assignee
Myriad Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myriad Genetics Inc filed Critical Myriad Genetics Inc
Publication of AU2002322481A1 publication Critical patent/AU2002322481A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002322481A 2001-06-29 2002-07-01 Use of r-nsaid compounds for anti-hiv treatment Abandoned AU2002322481A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30253301P 2001-06-29 2001-06-29
US60/302,533 2001-06-29
US10/186,371 US20030027867A1 (en) 2001-06-29 2002-06-28 Use of R-NSAID compounds for anti-HIV treatment
US10/186,371 2002-06-28
PCT/US2002/022289 WO2003013424A2 (en) 2001-06-29 2002-07-01 Use of r-nsaid compounds for anti-hiv treatment

Publications (1)

Publication Number Publication Date
AU2002322481A1 true AU2002322481A1 (en) 2003-02-24

Family

ID=26882034

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002322481A Abandoned AU2002322481A1 (en) 2001-06-29 2002-07-01 Use of r-nsaid compounds for anti-hiv treatment

Country Status (6)

Country Link
US (1) US20030027867A1 (enExample)
EP (1) EP1420745A2 (enExample)
JP (1) JP2004538319A (enExample)
AU (1) AU2002322481A1 (enExample)
CA (1) CA2451691A1 (enExample)
WO (1) WO2003013424A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004086A1 (en) * 2000-04-13 2006-01-05 Mayo Foundation For Medical Education And Research Method of reducing Abeta42 and treating diseases
CA2406383A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research A.beta.42 lowering agents
US7074826B2 (en) * 2002-10-07 2006-07-11 Encore Pharmaceuticals, Inc. R-NSAID esters and their use
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
WO2005065069A2 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
KR20070004036A (ko) * 2004-04-29 2007-01-05 키스톤 리테이닝 월 시스템스, 아이엔씨 벽, 옹벽 및 그 외 유사한 것을 위한 베니어
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
CA2618985A1 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
US8110681B2 (en) * 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
GB2475359A (en) * 2009-11-11 2011-05-18 Biocopea Ltd A compound for use in treating a fulminant respiratory disorder

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1091403A (en) * 1964-01-24 1967-11-15 Boots Pure Drug Co Ltd Therapeutically active phenylalkane derivatives
FR1546478A (fr) * 1967-01-27 1968-11-22 Rhone Poulenc Sa Nouveaux dérivés de l'acide benzoyl-3 phénylacétique et leur préparation
US4089969A (en) * 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US4230724A (en) * 1979-07-16 1980-10-28 Allergan Pharmaceuticals, Inc. Method of treating vascularization of the eye with Flurbiprofen
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPH0610141B2 (ja) * 1986-02-14 1994-02-09 新技術事業団 エイズウイルス性疾患処置剤
DE3824353A1 (de) * 1988-07-19 1990-01-25 Paz Arzneimittelentwicklung Verfahren zur trennung von gemischen enantiomerer arylpropionsaeuren
JPH0248526A (ja) * 1988-08-08 1990-02-19 Sumitomo Pharmaceut Co Ltd インドメタシン注射剤およびその製造方法
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
DE4028906A1 (de) * 1990-09-12 1992-03-19 Paz Arzneimittelentwicklung Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
DE4140184C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Flurbiprofen enthaltendes Arzneimittel
US5331000A (en) * 1992-03-09 1994-07-19 Sepracor Inc. Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
DE69328838T2 (de) * 1992-03-13 2000-10-12 Sepracor Inc., Marlborough Antipyretische und analgetische verfahren und zusammensetzungen, die optisch reines r-etodolac enthalten
DE4216756C2 (de) * 1992-05-21 1994-08-25 Pharmatrans Sanaq Ag 2-Arylpropionsäure-Zubereitungen und Verfahren zu ihrer Herstellung
US5382591A (en) * 1992-12-17 1995-01-17 Sepracor Inc. Antipyretic and analgesic methods using optically pure R-ketorolac
DK169670B1 (da) * 1992-12-22 1995-01-09 Cheminova Agro As Fremgangsmåde til fremstilling af 2,3,5,6-tetrachlorpyridin
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
US5981592A (en) * 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US6160018A (en) * 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
US5677469A (en) * 1995-05-18 1997-10-14 Sepracor, Inc. Process for resolving chiral acids with 1-aminoindan-2-ols
US5858738A (en) * 1996-11-07 1999-01-12 Merck & Co., Inc. Ermophilane sesquiterpenoids as HIV intergrase inhibitors
US6331610B1 (en) * 1997-04-25 2001-12-18 Metatron, Inc. Method for treating AIDS and HIV infection using select peptides from the beta subunit of human chorionic gonadotropin
US6140349A (en) * 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
PT1143958E (pt) * 1998-09-03 2007-04-30 Univ Loma Linda Med Composição farmacêutica e utilização de rnsaid para o tratamento da inflamação.
IN189741B (enExample) * 1998-11-09 2003-04-19 Council Scient Ind Res

Also Published As

Publication number Publication date
US20030027867A1 (en) 2003-02-06
WO2003013424A3 (en) 2004-02-12
EP1420745A2 (en) 2004-05-26
JP2004538319A (ja) 2004-12-24
WO2003013424A2 (en) 2003-02-20
CA2451691A1 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
AU2002342613A1 (en) Treatment for wounds
AU2002257936A1 (en) Methods of well treatment
AU2001272849A1 (en) Composition for the treatment of osteoarthritis
AU2002361149A1 (en) Set of teeth
AU2002240359A1 (en) Pharmaceutical composition for the treatment of alopecia
AU2003258145A1 (en) Substituted phenylindoles for the treatment of hiv
AU2002322481A1 (en) Use of r-nsaid compounds for anti-hiv treatment
AU2001253749A1 (en) 2-fluorobenzenesulfonyl compounds for the treatment of inflammation
AUPR820301A0 (en) Treatment of a wide range of titanium oxide compounds
EP1461030A4 (en) AMINOALKYL-BENZOFURAN-5-OL COMPOUNDS FOR THE TREATMENT OF GLAUCOMA
AU2002322082A1 (en) Pharmaceutical composition for the treatment of viral infection
HK1064952A (en) Treatment of tuberculosis using immunomodulator compounds
AU2002327440A1 (en) Treatment of type i diabetes
AU2683500A (en) Compositions for the treatment of pain
AU2000263936A1 (en) Substance p analogs for the treatment of cancer
AU2002341485A1 (en) Treatment of polyaluminium compounds
AU2002251202A1 (en) Intimins for the prevention or treatment of infections: i
AU2000272704A1 (en) Use of compounds for the treatment of obesity
AU2001253560A1 (en) Methods of treatment
AU2002327697A1 (en) Compounds for the treatment of pain
AU2002304733A1 (en) Amino-aza-cyclohexanes for the treatment of malaria
HK1059380A (en) Phenylindoles for the treatment of hiv
HK1064949A (en) Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma
AU2002359282A1 (en) Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
AU2002246050A1 (en) Treatment of dandruff

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase